Imugene Limited (ASX: IMU) is a biotechnology company, having operations in America and Europe is working specifically in the clinical stage of immuno-oncology. Immuno-oncology is an area of research that helps the body to fight cancer through its own immune system. The company’s platform technologies which are being developed by Medical University Vienna and Ohio State University helps the body to activate the immune system to generate antibodies to fight against cancer, which potentially achieves results similar or greater to synthetically manufactured monoclonal antibody therapies. The company’s main aim is to help and improve the treatment of cancer and to improve the lives of millions of cancer patients.
On 3rd April 2019, the company presented positive new data on the PD-1 mimotope cancer vaccine program with affiliation with Medical University Vienna at the 2019 Annual Meeting of American Association for Cancer Research (AACR).
The presentation entitled “PD1 B cell mimotopes with functional PD1-PDL1 blocking capacity and anti-tumor activity: New strategy for multi-level cancer immunotherapy” was presented by Dr Joshua Tobias from the Medical University Vienna.
Dr Tobias and Professor Ursula Wiedermann from the Medical University Vienna along with leading researchers from the University of Gothenburg Sweden, the University of Veterinary Medicine Vienna and the Vienna Cancer Centre Austria have authored the presentation.
Some of the highlights of the presentation were;
- Prof Wierdermann led the research which successfully inhibited tumor growth in a syngeneic mouse model of HER-2+ breast cancer via both active and passive immunisation strategies with PD-1 targeting B-cell cancer vaccines.
- As far as the active immunisation study is concerned which is of greatest interest and potential value to cancer researchers, the surrogate vaccine derived from mouse PD-1 was able to “brake tolerance” thereby generating a sustained antibody response to the self-protein PD-1
- The findings from the research provided a proof of concept and validation for the human PD-1 cancer vaccine KEY-Vaxx
The company has constantly been working on the research process of its other products. Apart from the data presentation of PD-1 mimotope cancer vaccines, the company also presented the research data of their other products namely PD-1 KEY-Vaxx and HER-2 B-Vaxx Cancer Vaccines and HER-Vaxx Cancer Vaccine on 2nd April 2019 at the American Association for Cancer Research 2019 Annual Meeting
The research uncovered, the KEY-Vaxx presentation exhibited that when it is combined with B-Vaxx, it gets more effective in fighting cancer and in reducing tumor growth. This composition of KEY-Vaxx and B-Vaxx vaccines was also found to be safe and did not appear to exhibit harmful or autoimmunity.
The research data of Phase Ib study of HER-Vaxx cancer vaccine was encouraging as the overall data was positive which evidently helped to support the B-cell platform cancer vaccine strategy for curing HER-2 positive gastric cancer.
On 20th March 2019 the company also provided guidance for KEY-Vaxx cancer vaccine.
On the technical front, the stock closed at A$ 0.020 on ASX (as on 3rd April 2019) trading up by 5.263% as compared to the previous day’s close. In the last six months, the stock has fallen by 9.5% while the YTD return stands at 5.56%.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.